50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
NASDAQ:ARQT

Arcutis Biotherapeutics - ARQT Stock Forecast, Price & News

$18.30
+0.09 (+0.49%)
(As of 09/27/2022 05:10 PM ET)
Add
Compare
Today's Range
$17.89
$19.03
50-Day Range
$17.85
$26.95
52-Week Range
$13.59
$27.40
Volume
770,776 shs
Average Volume
436,940 shs
Market Capitalization
$943.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.50

Arcutis Biotherapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
179.2% Upside
$50.60 Price Target
Short Interest
Bearish
12.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Arcutis Biotherapeutics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$737,101 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.45) to ($4.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

490th out of 1,071 stocks

Pharmaceutical Preparations Industry

225th out of 531 stocks

ARQT stock logo

About Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARQT Stock News Headlines

Arcutis Biotherapeutics' (ARQT) Buy Rating Reiterated at Jonestrading
Arcutis Biotherapeutics, Inc. (ARQT)
What 4 Analyst Ratings Have To Say About Arcutis Biotherapeutics
Arcutis Biotherapeutics: A Name To Accumulate
ARQT Crosses Below Key Moving Average Level
See More Headlines
Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARQT Company Calendar

Last Earnings
8/04/2022
Today
9/27/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARQT
Fax
N/A
Employees
147
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.60
High Stock Price Forecast
$57.00
Low Stock Price Forecast
$46.00
Forecasted Upside/Downside
+170.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-206,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.92 per share

Miscellaneous

Free Float
39,704,000
Market Cap
$943.60 million
Optionable
Not Optionable
Beta
0.28

Key Executives

  • Mr. Todd Franklin Watanabe M.A.Mr. Todd Franklin Watanabe M.A. (Age 54)
    Pres, CEO & Director
    Comp: $940.2k
  • Dr. Bhaskar  Chaudhuri Ph.D.Dr. Bhaskar Chaudhuri Ph.D. (Age 67)
    Co-Founder & Independent Director
    Comp: $60.58k
  • Mr. Scott L. BurrowsMr. Scott L. Burrows (Age 45)
    CFO & Principal Accounting Officer
    Comp: $617.87k
  • Dr. David W. Osborne Ph.D. (Age 61)
    Chief Technical Officer
    Comp: $584.55k
  • Dr. Patrick E. Burnett M.D. (Age 50)
    Ph.D., Sr. VP & Chief Medical Officer
    Comp: $700.1k
  • Mr. Matthew Richard Moore (Age 48)
    Sr. VP & Chief Bus. Officer
    Comp: $560.07k
  • Ms. Patricia A. TurneyMs. Patricia A. Turney (Age 55)
    Sr. VP of Operations
  • Mr. Eric McIntyre
    Head of Investor Relations
  • Ms. Courtney Barton (Age 39)
    Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer
  • Mr. Masaru Matsuda Esq. (Age 51)
    J.D., Sr. VP, Gen. Counsel & Corp. Sec.













ARQT Stock - Frequently Asked Questions

Should I buy or sell Arcutis Biotherapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARQT shares.
View ARQT analyst ratings
or view top-rated stocks.

What is Arcutis Biotherapeutics' stock price forecast for 2022?

6 brokerages have issued twelve-month price targets for Arcutis Biotherapeutics' shares. Their ARQT share price forecasts range from $45.00 to $57.00. On average, they expect the company's stock price to reach $50.40 in the next year. This suggests a possible upside of 176.8% from the stock's current price.
View analysts price targets for ARQT
or view top-rated stocks among Wall Street analysts.

How have ARQT shares performed in 2022?

Arcutis Biotherapeutics' stock was trading at $20.74 on January 1st, 2022. Since then, ARQT shares have decreased by 12.2% and is now trading at $18.21.
View the best growth stocks for 2022 here
.

When is Arcutis Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ARQT earnings forecast
.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its quarterly earnings results on Thursday, August, 4th. The company reported ($1.31) EPS for the quarter, beating analysts' consensus estimates of ($1.38) by $0.07.

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

(ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

What is Arcutis Biotherapeutics' stock symbol?

Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (14.96%), Bain Capital Life Sciences Investors LLC (5.82%), Point72 Asset Management L.P. (3.85%), State Street Corp (2.71%), Pictet Asset Management SA (1.79%) and Franklin Resources Inc. (1.54%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Jonathan Silverstein, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends
.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcutis Biotherapeutics' stock price today?

One share of ARQT stock can currently be purchased for approximately $18.21.

How much money does Arcutis Biotherapeutics make?

Arcutis Biotherapeutics (NASDAQ:ARQT) has a market capitalization of $938.96 million. The company earns $-206,360,000.00 in net income (profit) each year or ($5.14) on an earnings per share basis.

How many employees does Arcutis Biotherapeutics have?

The company employs 147 workers across the globe.

How can I contact Arcutis Biotherapeutics?

Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The official website for the company is www.arcutis.com. The company can be reached via phone at 805-418-5006 or via email at ir@arcutis.com.

This page (NASDAQ:ARQT) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.